Orchard Therapeutics company

Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases. Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders.
We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy. Our mission is to translate results from pre-clinical and early clinical research into commercially approved gene therapies for patients around the world.
Technology: Regenerative Medicine
Industry: Regenerative Medicine
Headquarters: London, England, United Kingdom
Founded Date: 7-7
Employees Number: 51-100
Funding Status: IPO
Investors Number: 24
Total Funding: $310.5M
Estimated Revenue: $1M to $10M
Last Funding Type: Series C

Visit Website
info@orchard-tx.com
@orchard_tx
Register and Claim Ownership